Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice-Feasibility Demonstration.

MRI blood–brain barrier disruption neurodegenerative diseases non-invasive pulsed electrical fields treatment response assessment maps

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
27 Jan 2021
Historique:
received: 26 11 2020
revised: 06 01 2021
accepted: 23 01 2021
entrez: 30 1 2021
pubmed: 31 1 2021
medline: 31 1 2021
Statut: epublish

Résumé

The blood-brain barrier (BBB) is a major hurdle for the treatment of central nervous system disorders, limiting passage of both small and large therapeutic agents from the blood stream into the brain. Thus, means for inducing BBB disruption (BBBd) are urgently needed. Here, we studied the application of low pulsed electrical fields (PEFs) for inducing BBBd in mice. Mice were treated by low PEFs using electrodes pressed against both sides of the skull (100-400 square 50 µs pulses at 4 Hz with different voltages). BBBd as a function of treatment parameters was evaluated using MRI-based treatment response assessment maps (TRAMs) and Evans blue extravasation. A 3D numerical model of the mouse brain and electrodes was constructed using finite element software, simulating the electric fields distribution in the brain and ensuring no significant temperature elevation. BBBd was demonstrated immediately after treatment and significant linear regressions were found between treatment parameters and the extent of BBBd. The maximal induced electric field in the mice brains, calculated by the numerical model, ranged between 62.4 and 187.2 V/cm for the minimal and maximal applied voltages. These results demonstrate the feasibility of inducing significant BBBd using non-invasive low PEFs, well below the threshold for electroporation.

Identifiants

pubmed: 33513968
pii: pharmaceutics13020169
doi: 10.3390/pharmaceutics13020169
pmc: PMC7911365
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Israel Science foundation (ISF)
ID : 1922/18

Références

Front Neuroeng. 2014 Aug 05;7:32
pubmed: 25140148
J Med Eng Technol. 2018 Feb;42(2):128-139
pubmed: 29569970
J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72
pubmed: 22929442
Bioelectrochemistry. 2020 Aug;134:107521
pubmed: 32251984
J Neural Eng. 2010 Feb;7(1):16005
pubmed: 20075507
Cancers (Basel). 2020 Jan 25;12(2):
pubmed: 31991784
Int J Nanomedicine. 2019 Jul 30;14:5895-5909
pubmed: 31440051
PLoS One. 2012;7(11):e50482
pubmed: 23226293
Neuro Oncol. 2020 Aug 19;:
pubmed: 32812637
IEEE Trans Biomed Eng. 2007 May;54(5):773-81
pubmed: 17518273
Neuro Oncol. 2015 Mar;17(3):457-65
pubmed: 25452395
Pharmaceutics. 2015 Aug 03;7(3):175-87
pubmed: 26247958
Mov Disord. 2019 Jul;34(7):1073-1078
pubmed: 31145831
Bioelectrochemistry. 2014 Oct;99:30-9
pubmed: 24976141
Oncol Res Treat. 2019;42(1-2):47-51
pubmed: 30537762
Theranostics. 2018 Feb 5;8(6):1481-1493
pubmed: 29556336
Surgery. 2020 Oct;168(4):610-616
pubmed: 32631655
CNS Drugs. 2017 Feb;31(2):109-133
pubmed: 28101766
Curr Protoc Immunol. 2019 Sep;126(1):e83
pubmed: 31483106
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818785285
pubmed: 30071778
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183298
pubmed: 32353377
Comput Methods Programs Biomed. 2020 Nov;196:105706
pubmed: 32818721
J Neurooncol. 2021 Jan;151(1):65-73
pubmed: 32112296
Sci Rep. 2014 Oct 10;4:6588
pubmed: 25300427
Magn Reson Med. 1991 Feb;17(2):357-67
pubmed: 2062210
Neuroreport. 2018 Aug 1;29(11):924-931
pubmed: 29762248
Cancers (Basel). 2019 Nov 23;11(12):
pubmed: 31771214
Annu Rev Biomed Eng. 2014 Jul 11;16:295-320
pubmed: 24905876
J Neurosci Methods. 2006 Mar 15;151(2):262-7
pubmed: 16181683
Sci Rep. 2020 Feb 7;10(1):2178
pubmed: 32034261
Neuroscience. 2009 Jul 7;161(3):926-39
pubmed: 19362131
Med Phys. 2014 Dec;41(12):124301
pubmed: 25471985
Magn Reson Med. 2010 Mar;63(3):691-700
pubmed: 20187179
Med Phys. 2017 Sep;44(9):4968-4980
pubmed: 28594449
Int J Biol Sci. 2010 Dec 26;7(1):1-8
pubmed: 21209786
PLoS One. 2012;7(8):e42817
pubmed: 22900052
Drug Deliv. 2019 Dec;26(1):459-469
pubmed: 30957567
Radiol Oncol. 2016 Feb 16;50(1):28-38
pubmed: 27069447
J Neural Eng. 2006 Dec;3(4):306-15
pubmed: 17124335
Stat Med. 1996 Feb 28;15(4):343-59
pubmed: 8668866

Auteurs

Shirley Sharabi (S)

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.

David Last (D)

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.

Dianne Daniels (D)

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.

Ido Didi Fabian (ID)

Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.

Dana Atrakchi (D)

The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.

Yael Bresler (Y)

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.

Sigal Liraz-Zaltsman (S)

The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Department of Pharmacology, Institute for Drug Research, Hebrew University, Jerusalem 9112001, Israel.
Institute for Health and Medical Professions, Department of Sports Therapy, Ono Academic College, Kiryat Ono 5545173, Israel.

Itzik Cooper (I)

The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Interdisciplinary Center Herzliya, Herzliya 4610101, Israel.

Yael Mardor (Y)

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 5262000, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.

Classifications MeSH